Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilotrif

- PMLiVE

Candel announces promising results for immunotherapy candidate in pancreatic cancer

Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

- PMLiVE

Abu Dhabi launches clinical genomic medicine and genetic counselling programme

More than 400,000 genetic samples have been collected as part of the programme

- PMLiVE

Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Merck’s Keytruda combination granted FDA approval for biliary tract cancer

Approximately 20,000 people are diagnosed with the disease each year in the US

- PMLiVE

AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

- PMLiVE

Kite and Epic Bio announce cancer cell therapy collaboration agreement

The partnership centres around Epic Bio’s proprietary gene regulation platform

- PMLiVE

Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn

The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate

- PMLiVE

Boehringer Ingelheim reveals new corporate branding

The evolved brand includes the company’s first-ever brand claim, Life Forward

- PMLiVE

Innovative Trials has been shortlisted in the PMEA Awards

Innovative Trials finalist in the Support Agency of the Year at the annual PMEA industry awards.

Innovative Trials

- PMLiVE

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

Roche collaborates with Ibex and Amazon Web to improve cancer diagnosis

Integrated artificial intelligence-based tools will support clinicians’ decisions in cancer diagnosis

- PMLiVE

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

Approximately 16,000 people in the US are diagnosed with myelodysplastic syndromes every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links